Pipeline forecasting best practices for 2026 for healthcare and life sciences in emerging markets
The current, revised best practices for pipeline forecasting — updated for what actually works in the buyer environment of 2026. Written for commercial leaders at healthtech, medtech, and life-sciences companies in emerging markets.
This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in emerging markets. In this market, emerging-market buyers reward patient capital, currency-aware pricing, and a real local operating footprint, so the way you install pipeline forecasting has to be shaped to that reality from day one.
Best practices for pipeline forecasting have shifted. The 2022 playbook does not survive the current buyer environment. This is the update.
Best practice one: fewer accounts, sharper triggers. Capital allocation depends on believing the number, and generic coverage is now negative signal.
Best practice two: publish forecast variance vs actuals per quarter weekly. If leadership does not see the number, the model quietly drifts.
Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in emerging markets it is compounded by the fact that operating footprint and pricing fit, not brand awareness is what actually gates growth. Pipeline forecasting is only useful here when it is pointed at both constraints at once.
Best practice three: separate the sending infrastructure from the primary brand. Deliverability is a strategic asset.
Best practice four: name a single owner. Committees produce compromise; owners produce numbers.
Best practice five: pre-write kill criteria. A stated failure threshold is what prevents the sunk-cost trap.
Best practice six: run monthly retrospectives that are honest about what did not work. Pipeline forecasting improves faster on failure data than on success data.
Concretely for healthcare and life sciences in emerging markets: the healthcare teams that install this get past procurement instead of dying in it, and the teams that install this early own the category before Western vendors even show up. That is the reason it is worth installing pipeline forecasting deliberately for this market rather than importing a playbook designed for somewhere else.
Frequently asked questions
RevOps · healthcare · emerging markets — answered
- Does pipeline forecasting work for healthcare and life sciences in emerging markets?
- Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in emerging markets, emerging-market buyers reward patient capital, currency-aware pricing, and a real local operating footprint. The healthcare teams that install this get past procurement instead of dying in it.
- What changed in pipeline forecasting best practices for 2026?
- Buyers are less tolerant of generic coverage; specificity and trigger quality now dominate.
- Which best practice is most under-implemented?
- Pre-written kill criteria. Almost no team has them; every team benefits from them.
- Do best practices change by company size?
- Governance scales with size; core principles remain identical.
- How do I know a best practice is working?
- Forecast variance vs actuals per quarter improves, and improvements survive a month.
- What is the emerging markets-specific pitfall when running pipeline forecasting for healthcare?
- Importing a playbook that was built for another market. In emerging markets, emerging-market buyers reward patient capital, currency-aware pricing, and a real local operating footprint — the install has to reflect that.
Growth Broker editorial
Filed under revops · healthcare · emerging markets